Monitoring Antiplatelet Therapy During Peripheral Vascular and Coronary Interventions

Techniques in Vascular and Interventional Radiology

Volumn 9, Issue 2, 2006, Pages 56-63

  Mahmud, Ehtisham ^a   Ang, Lawrence ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antiplatelet medications; platelet function assay; platelets

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ALGORITHM; ARTICLE; ASSAY; BLEEDING; BLOOD CLOTTING TIME; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; HEART INFARCTION; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; ISCHEMIA; LABORATORY TEST; LOADING DRUG DOSE; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; TREATMENT FAILURE;

ALGORITHMS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; CORONARY THROMBOSIS; HUMANS; MONITORING, INTRAOPERATIVE; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; RADIOLOGY, INTERVENTIONAL; THROMBOSIS;

EID: 34247612961     PISSN: 10892516     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.tvir.2006.12.006     Document Type: Article

References (58)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
2. Nguyen T.A., Diodati J.G., and Pharand C. Resistance to Clopidogrel: a review of the evidence. J Am Coll Cardiol 45 (2005) 1157-1164
3. Michelson A.D. Platelet function testing in cardiovascular diseases. Circulation 110 (2004) e489-e493
4. Han J., Lim C.W., Watanabe N., et al. Reconstructing and deconstructing agonist-induced activation of integrin αIIbβ3. Curr Biol 16 (2006) 1796-1806
5. Born G.V.R. Aggregation of blood platelets by adenosine and its reversal. Nature 194 (1962) 927-929
6. O'Brien J.R. Platelet aggregation Part II: some results of a new method. J Clin Pathol 15 (1962) 452-455
7. Michelson A.D., Frelinger III A.L., and Furman M.I. Current options in platelet function testing. Am J Cardiol 98 (2006) S4-S10
8. Michelson A.D., Cattaneo M., Eidelboom J.W., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3 (2005) 1309-1311
9. Harrison P., Segal H., Blasbery K., et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36 (2005) 1001-1005
10. Alberts M.J., Bergman D.L., Molner E., et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35 (2004) 175-178
11. Hezard N., Metz D., Mazeyrollas P., et al. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thromb Haemost 83 (2000) 540-544
12. Madan M., Berkowitz S.D., Christie D.J., et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 141 (2001) 226-233
13. Madan M., Berkowitz S.D., Christie D.J., et al. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am Heart J 144 (2002) 151-158
14. Hayward C.P.M., Harrison P., Cattaneos M., et al. Platelet function Analyzer (PFA-100) closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 4 (2006) 1433-1434
15. Malanin A.I., Spergling M., Muhlestein B., et al. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 15 (2004) 295-301
16. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 23 (1997) 349-356
17. Antithrombitic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
18. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2 (1988) 349-360
19. Berger P.B., and Steinhubl S. Clinical implications of percutaneous coronary intervention-Clopidogrel in Unstable Angina to prevent Recurrent Events (PCI-CURE) Study: a US perspective. Circulation 106 (2002) 2284
20. Cairns J.A., Gent M., Singer J., et al. Aspirin, Sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 313 (1985) 1369-1375
21. The Risk Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336 (1990) 827-830
22. Steinhubl S.R., Berger P.B., Mann III J.T., et al., Credo Investigators. Clopidogrel for the reduction of events during observation. JAMA 289 (2003) 1926-1927
23. Fox K.A., Mehta S.R., Peters R., et al. Clopidogrel in unstable angina to prevent recurrent ischemic events trial. Circulation 110 (2004) 1202-1208
24. Muller C., Buttner H.J., Petersen J., et al. A randomized comparison of clopidogrel and aspirin versus ticlodipine and aspirin after the placement of coronary-artery stents. Circulation 101 (2000) 590-593
25. Braunwald E., Antman E.M., Beasley J.W., et al., American College of Cardiology, American Heart Association, Committee on the Management of Patients with Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 (2002) 1366-1374
26. von Beckerath N., Taubert D., Pogatsa-Murray G., et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112 (2005) 2946-2950
27. Patti G., Colonna G., Pasceri V., et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
28. Montalescot G., Sideris G., Meuleman C., et al., ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48 (2006) 931-938
29. Kastrati A., Mehilli J., Neumann F.J., et al. Intracoronary Stenting and Antithrombotic Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. JAMA 295 (2006) 1531-1538
30. Markus K.S., Droste D.W., Kaps M., et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 111 (2005) 2233-2240
31. Clagett G.P., Sobel M., Jackson M.R., et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 609S-626S
32. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
33. Yusuf S., Zhao F., Mehta S.R., et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
34. Bhatt D.L., Fox K.A., Hacke W., et al., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombic events. N Engl J Med 354 (2006) 1706-1717
35. Brener S.J., Barr L.A., Burchenal, et al., ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 98 (1998) 734-741
36. Montalescot G., Barragan P., Wittenberg O., et al., ADMIRAL Investigators. Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 (2001) 1895-1903
37. Neumann F.J., Kastrati A., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 35 (2000) 915-921
38. Stone G.W., Grines C.L., Cox D.A., et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346 (2002) 957-966
39. Antoniucci D., Migliorini A., Parodi G., et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 109 (2004) 1704-1706
40. Moser M., Bertram U., Peter K., et al. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol 41 (2003) 586-592
41. Stone G.W., Moliterno D.J., Bertrand M., et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. Circulation 105 (2002) 2347-2354
42. Kabbani S.S., Aggarwal A., Terrien E.F., et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 89 (2002) 1452
43. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103 (2001) 2572-2578
44. Rocha-Singh K.J., and Rutherford J. Glycoprotein IIb-IIIa receptor inhibition with eptifibatide in percutaneous intervention for symptomatic peripheral vascular disease: the circulate pilot trial. Catheter Cardiovasc Interv 66 (2005) 470-473
45. Allie D.E., Hebert C.J., Lirtzman M.D., et al. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome. J Invasive Cardiol 17 (2005) 427-432
46. Wholey M.H., Wholey M.H., Eles G., et al. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting. J Endovasc Ther 10 (2003) 33-41
47. Barkhoudarian G., Ali M.J., Deveikis J., and Thompsom B.G. Intravenously administered abciximab in the management of early cerebral ischemia after carotid endarterectomy: case report. Neurosurgery 55 (2004) 709
48. Grotemeyer K.H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 63 (1991) 587-593
49. Jaremo P., Lindahl T.L., Fransson S.G., et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252 (2002) 233-238
50. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
51. Malinin A., Pokov A., Spergling M., et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERIfy Thrombosis risk Assessment (VERITAS) study. Thromb Res 119 (2007) 277-284
52. Chen W.H., Lee P.Y., Ng W., et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
53. Hochholzer W., Trenk D., Bestehorn H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
54. Kastrati A., Schuhlen H., Hausleiter J., et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation 96 (1997) 462-467
55. Chaturvedi S., and Yadav J.S. The role of antiplatelet therapy in carotid stenting for ischemic stroke prevention. Stroke 37 (2006) 1572-1577
56. Lefkovits J., Plow E.F., and Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332 (1995) 1553-1559
57. Steinhubl S.R. The VerifyNow System. In: Michelson A.D. (Ed). Platelets. (ed 2) (2006), Elsevier/Academic Press, San Diego, CA 509-518
58. Steinhubl S.R., and Kereiakes D.J. Ultegra rapid platelet function analyzer. In: Michelson A.D. (Ed). Platelets (2002), Academic Press/Elsevier Science, New York, NY 317-324